Kurisu Tada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kurisu Tada has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo
6 shared publications - Yoshinori Taniguchi
From the Department of Endocrinology, Metabolism, Nephrology, and Rheumatology, Kochi Medical School Hospital, Kochi University, Nankoku, Kochi, Japan
3 shared publications - Anna Molto
Service de Rhumatologie, Hôpital Bichat, APHP. Nord, Paris, France
2 shared publications - Clementina López-Medina
Medical and Surgical Sciences Department, University of Cordoba, Cordoba, Spain
2 shared publications - Gautam A. Deshpande
Juntendo University
2 shared publications - Haruki Sawada
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study
This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions. Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region. Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, p = 0.02). Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.
- 3 November 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Open AccessDisease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study
This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions. Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region. Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, p = 0.02). Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.
- 25 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Intracranial invasion of granulomatous sinusitis: report of a rare case of granulomatosis with polyangiitis
The involvement of the central nervous system with granulomatosis with polyangiitis (GPA) is uncommon, and the formation of intracranial mass lesions is particularly rare. We describe the case of a Japanese woman in her thirties with GPA initially limited to the upper respiratory tract. Twelve years after the disease was onset, brain magnetic resonance imaging revealed a lobulated mass in the frontal lobe, and computed tomography findings suggested direct extension of granulomatous inflammation from the paranasal sinuses through the cribriform plate. Due to the risk of infection associated with cribriform plate destruction, surgical resection was performed for both diagnostic and preventive purposes. Histopathological examination of the resected intracranial lesion revealed necrotising granulomas without evidence of infection, consistent with GPA. Postoperatively, a moderate dose of prednisolone and rituximab was administered, resulting in clinical and serological remission. This case highlights a rare intracranial manifestation of GPA caused by direct contiguous spread from the paranasal sinuses, which can occur in the absence of systemic symptoms. Although sinonasal involvement is typically regarded as non-severe, the presence of bony destruction may signal a potentially organ-threatening course.
- 25 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Intracranial invasion of granulomatous sinusitis: report of a rare case of granulomatosis with polyangiitis
The involvement of the central nervous system with granulomatosis with polyangiitis (GPA) is uncommon, and the formation of intracranial mass lesions is particularly rare. We describe the case of a Japanese woman in her thirties with GPA initially limited to the upper respiratory tract. Twelve years after the disease was onset, brain magnetic resonance imaging revealed a lobulated mass in the frontal lobe, and computed tomography findings suggested direct extension of granulomatous inflammation from the paranasal sinuses through the cribriform plate. Due to the risk of infection associated with cribriform plate destruction, surgical resection was performed for both diagnostic and preventive purposes. Histopathological examination of the resected intracranial lesion revealed necrotising granulomas without evidence of infection, consistent with GPA. Postoperatively, a moderate dose of prednisolone and rituximab was administered, resulting in clinical and serological remission. This case highlights a rare intracranial manifestation of GPA caused by direct contiguous spread from the paranasal sinuses, which can occur in the absence of systemic symptoms. Although sinonasal involvement is typically regarded as non-severe, the presence of bony destruction may signal a potentially organ-threatening course.
- 25 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5776-5784
SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
- 25 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5776-5784
SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S63-S66
A Systemic Lupus Erythematosus Patient with Cutaneous Mycobacterium haemophilum Infection under Belimumab Treatment: A Case Report
Kim J, et al. Ann Dermatol. 2023 May;35:e45. https://doi.org/10.5021/ad.21.077
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S63-S66
Open AccessA Systemic Lupus Erythematosus Patient with Cutaneous Mycobacterium haemophilum Infection under Belimumab Treatment: A Case Report
Kim J, et al. Ann Dermatol. 2023 May;35:e45. https://doi.org/10.5021/ad.21.077
- 9 May 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (10) , 1751-1766
Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis
The purpose of this study was to clarify the clinical characteristics of spondyloarthritis (SpA) patients with inflammatory bowel disease (IBD) compared to those without IBD. Furthermore, among patients with SpA and IBD, we aimed to clarify what clinical characteristics lead rheumatologists to diagnose “IBD-related arthritis.” Utilizing SpA and psoriatic arthritis (PsA) patients’ data from an international, cross-sectional, observational study, we analyzed information on demographics and disease characteristics, dichotomizing patients by IBD status. The presence or absence of IBD was determined based on data collection of treating rheumatologists. Patients with SpA (including PsA) and IBD were also categorized based on treating rheumatologists’ definitive diagnosis in regard to SpA type, and compared by whether the patients had IBD-related arthritis or not. Among 4465 SpA patients, 287 (6.4%, 95%CI 5.7–7.2%) were identified with IBD. Compared to SpA patients without IBD, patients with SpA and IBD had a longer diagnostic delay (5.1 vs. 2.9 years, p < 0.001). In patients with SpA and IBD, 111 (38.7%, 95%CI 33.0–44.6%) were diagnosed with IBD-related arthritis. Multivariable analyses showed that HLA-B27 positivity [OR = 0.35, (95%CI 0.15–0.80)], psoriasis [OR = 0.14, (95%CI 0.04–0.50)], IBD as first symptom of SpA [OR = 3.32, (95%CI 1.84–6.01)], and need for IBD-specific treatment [OR = 5.41, (95%CI 2.02–14.50)] were independently associated with the definitive diagnosis of IBD-related arthritis. Collaboration with gastroenterologists is needed to shorten the diagnostic delay in patients with SpA and IBD. The recognition of the factors for the diagnosis of “IBD-related arthritis” may lead to the elucidation of the pathogenesis.
- 9 May 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (10) , 1751-1766
Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis
The purpose of this study was to clarify the clinical characteristics of spondyloarthritis (SpA) patients with inflammatory bowel disease (IBD) compared to those without IBD. Furthermore, among patients with SpA and IBD, we aimed to clarify what clinical characteristics lead rheumatologists to diagnose “IBD-related arthritis.” Utilizing SpA and psoriatic arthritis (PsA) patients’ data from an international, cross-sectional, observational study, we analyzed information on demographics and disease characteristics, dichotomizing patients by IBD status. The presence or absence of IBD was determined based on data collection of treating rheumatologists. Patients with SpA (including PsA) and IBD were also categorized based on treating rheumatologists’ definitive diagnosis in regard to SpA type, and compared by whether the patients had IBD-related arthritis or not. Among 4465 SpA patients, 287 (6.4%, 95%CI 5.7–7.2%) were identified with IBD. Compared to SpA patients without IBD, patients with SpA and IBD had a longer diagnostic delay (5.1 vs. 2.9 years, p < 0.001). In patients with SpA and IBD, 111 (38.7%, 95%CI 33.0–44.6%) were diagnosed with IBD-related arthritis. Multivariable analyses showed that HLA-B27 positivity [OR = 0.35, (95%CI 0.15–0.80)], psoriasis [OR = 0.14, (95%CI 0.04–0.50)], IBD as first symptom of SpA [OR = 3.32, (95%CI 1.84–6.01)], and need for IBD-specific treatment [OR = 5.41, (95%CI 2.02–14.50)] were independently associated with the definitive diagnosis of IBD-related arthritis. Collaboration with gastroenterologists is needed to shorten the diagnostic delay in patients with SpA and IBD. The recognition of the factors for the diagnosis of “IBD-related arthritis” may lead to the elucidation of the pathogenesis.
- Open Access
- 23 December 2021
- Published by Hindawi Limited in Case Reports in Rheumatology
- Vol. 2021, 1-4
Tonsillitis-Related Arthritis: Advanced Understandings of Tonsillitis and Sterile Inflammatory Arthritis
A 49-year-old man developed acute aseptic arthritis of the nonmigratory and asymmetrical type in his knee, ankle, and bilateral metatarsal joints 13 days after treatment with antibiotics for acute tonsillitis. He was diagnosed with tonsillitis-related arthritis after other rheumatic diseases were ruled out. Treatment with salazosulfapyridine, methotrexate, and methylprednisolone for 3 months did not completely improve. Then, tonsillectomy was undertaken and arthritis rapidly improved. Finegoldia magna (previously Peptostreptococcus magnus) was cultured from the microabscesses of the resected tonsils. After outpatient follow-up, the patient did not experience a relapse of arthritis for more than 2.7 years without any treatment. Poststreptococcal reactive arthritis (PSRA) is well described. However, up to 40 of patients with tonsillitis-related arthritis did not demonstrate evidence of streptococcal infection. It is noted that tonsillectomy is necessary to remove the tonsillar microabscesses and eradicate bacterial infection of the tonsils, especially for patients with a prolonged and/or recurrent course of PSRA and/or tonsillitis-related arthritis.
- 23 December 2021
- Published by Hindawi Limited in Case Reports in Rheumatology
- Vol. 2021, 1-4
Open AccessTonsillitis-Related Arthritis: Advanced Understandings of Tonsillitis and Sterile Inflammatory Arthritis
A 49-year-old man developed acute aseptic arthritis of the nonmigratory and asymmetrical type in his knee, ankle, and bilateral metatarsal joints 13 days after treatment with antibiotics for acute tonsillitis. He was diagnosed with tonsillitis-related arthritis after other rheumatic diseases were ruled out. Treatment with salazosulfapyridine, methotrexate, and methylprednisolone for 3 months did not completely improve. Then, tonsillectomy was undertaken and arthritis rapidly improved. Finegoldia magna (previously Peptostreptococcus magnus) was cultured from the microabscesses of the resected tonsils. After outpatient follow-up, the patient did not experience a relapse of arthritis for more than 2.7 years without any treatment. Poststreptococcal reactive arthritis (PSRA) is well described. However, up to 40 of patients with tonsillitis-related arthritis did not demonstrate evidence of streptococcal infection. It is noted that tonsillectomy is necessary to remove the tonsillar microabscesses and eradicate bacterial infection of the tonsils, especially for patients with a prolonged and/or recurrent course of PSRA and/or tonsillitis-related arthritis.
- Open Access
- 1 May 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (8) , 1387-1398
Expanding the spectrum of reactive arthritis (ReA): classic ReA and infection-related arthritis including poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA
Reactive arthritis (ReA) is a form of sterile arthritis that occurs secondary to an extra-articular infection in genetically predisposed individuals. The extra-articular infection is typically an infection of the gastrointestinal tract or genitourinary tract. Infection-related arthritis is a sterile arthritis associated with streptococcal tonsillitis, extra-articular tuberculosis, or intravesical instillation of bacillus Calmette–Guérin (iBCG) therapy for bladder cancer. These infection-related arthritis diagnoses are often grouped with ReA based on the pathogenic mechanism. However, the unique characteristics of these entities may be masked by a group classification. Therefore, we reviewed the clinical characteristics of classic ReA, poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA. Considering the diversity in triggering microbes, infection sites, and frequency of HLA-B27, these are different disorders. However, the clinical symptoms and intracellular parasitism pathogenic mechanism among classic ReA and infection-related arthritis entities are similar. Therefore, poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA could be included in the expanding spectrum of ReA, especially based on the pathogenic mechanism.
- 1 May 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (8) , 1387-1398
Open AccessExpanding the spectrum of reactive arthritis (ReA): classic ReA and infection-related arthritis including poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA
Reactive arthritis (ReA) is a form of sterile arthritis that occurs secondary to an extra-articular infection in genetically predisposed individuals. The extra-articular infection is typically an infection of the gastrointestinal tract or genitourinary tract. Infection-related arthritis is a sterile arthritis associated with streptococcal tonsillitis, extra-articular tuberculosis, or intravesical instillation of bacillus Calmette–Guérin (iBCG) therapy for bladder cancer. These infection-related arthritis diagnoses are often grouped with ReA based on the pathogenic mechanism. However, the unique characteristics of these entities may be masked by a group classification. Therefore, we reviewed the clinical characteristics of classic ReA, poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA. Considering the diversity in triggering microbes, infection sites, and frequency of HLA-B27, these are different disorders. However, the clinical symptoms and intracellular parasitism pathogenic mechanism among classic ReA and infection-related arthritis entities are similar. Therefore, poststreptococcal ReA, Poncet’s disease, and iBCG-induced ReA could be included in the expanding spectrum of ReA, especially based on the pathogenic mechanism.